- Home
- CINT vs TRVI Comparison
CINT vs TRVI Comparison
Compare CINT & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CINT
- TRVI
- Stock Information
- Founded
- CINT 1995
- TRVI 2011
- Country
- CINT Brazil
- TRVI United States
- Employees
- CINT N/A
- TRVI N/A
- Industry
- CINT EDP Services
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- CINT Technology
- TRVI Health Care
- Exchange
- CINT Nasdaq
- TRVI Nasdaq
- Market Cap
- CINT 803.4M
- TRVI 725.7M
- IPO Year
- CINT 2021
- TRVI 2019
- Fundamental
- Price
- CINT $5.57
- TRVI $6.85
- Analyst Decision
- CINT Buy
- TRVI Strong Buy
- Analyst Count
- CINT 7
- TRVI 9
- Target Price
- CINT $7.61
- TRVI $19.94
- AVG Volume (30 Days)
- CINT 87.5K
- TRVI 1.7M
- Earning Date
- CINT 08-15-2025
- TRVI 08-07-2025
- Dividend Yield
- CINT N/A
- TRVI N/A
- EPS Growth
- CINT 53.80
- TRVI N/A
- EPS
- CINT 0.24
- TRVI N/A
- Revenue
- CINT $444,135,000.00
- TRVI N/A
- Revenue This Year
- CINT $521.47
- TRVI N/A
- Revenue Next Year
- CINT $13.05
- TRVI N/A
- P/E Ratio
- CINT $22.96
- TRVI N/A
- Revenue Growth
- CINT 3.04
- TRVI N/A
- 52 Week Low
- CINT $4.42
- TRVI $2.36
- 52 Week High
- CINT $8.04
- TRVI $7.48
- Technical
- Relative Strength Index (RSI)
- CINT 43.06
- TRVI 64.33
- Support Level
- CINT $5.89
- TRVI $6.61
- Resistance Level
- CINT $5.94
- TRVI $7.05
- Average True Range (ATR)
- CINT 0.17
- TRVI 0.34
- MACD
- CINT -0.03
- TRVI 0.12
- Stochastic Oscillator
- CINT 23.33
- TRVI 95.12
About CINT CI&T Inc
CI&T Inc is engaged in providing strategy, design, and software engineering services to enable digital transformation for companies. The company mainly develops customizable software through the implementation of several software solutions, including Machine Learning, Artificial Intelligence (AI), Analytics, Cloud, and Mobility technologies. The majority of the revenue is generated from the North America and Europe, followed by Asia, Pacific and Japan.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.